Abstract
Glatiramer acetate and interferon-beta are approved first-line disease-modifying treatments (DMTs) for multiple sclerosis (MS).
DMTs can be associated with cutaneous adverse events, which may influence treatment adherence and patient quality of life.
In this systematic review, we aimed to provide an overview of the clinical spectrum and the incidence of skin reactions associated with DMTs.... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... geid/1316/